Fibroblast growth factor-23 and early decrements in kidney function: The heart and soul study

Nephrology Dialysis Transplantation

Volumn 25, Issue 3, 2010, Pages 993-997

  Ix, Joachim H ^a,b,c   Shlipak, Michael G ^d,e   Wassel, Christina L ^c   Whooley, Mary A ^d,e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Albuminuria; Chronic; Fibroblast growth factor 23; Kidney disease; Osteodystrophy

Indexed keywords

FIBROBLAST GROWTH FACTOR 23;

ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; OUTPATIENT; PRIORITY JOURNAL;

AGED; ALBUMINURIA; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CREATININE; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED;

EID: 77649227621     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp699     Document Type: Article

References (18)

1. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38
2. Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167: 879-885
3. Foley RN, Collins AJ, Ishani A, et al. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2008; 156: 556-563
4. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin d and 1, 25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008; 168: 1340-1349
5. Hagstrom E, Hellman P, Larsson TE, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009; 119: 2765-2771
6. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007; 18: 1637-1647
7. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
8. Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552
9. Isakova T, Gutierrez O, Shah A, et al. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Ne-phrol 2008; 19: 615-623
10. Ix JH, Chertow GM, Shlipak MG, et al. Fetuin-A and kidney function in persons with coronary artery disease-data from the Heart and Soul Study. Nephrol Dial Transplant 2006; 21: 2144-2151
11. Levey AS, Greene T, Kusek JW, et al. A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 2001; 11: A0828
12. Ix JH, Shlipak MG, Chertow GM, et al. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007; 115: 173-179
13. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3, 418 individuals with CKD. Am J Kidney Dis 2008; 51: 395-406
14. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348: 1656-1663
15. Toto RD. Microalbuminuria: definition, detection, and clinical significance. J Clin Hypertens (Greenwich) 2004; 6: 2-7
16. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266
17. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145: 237-246
18. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049-2060